MARKET

AGEN

AGEN

Agenus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.260
+0.030
+0.93%
After Hours: 3.230 -0.03 -0.92% 18:11 05/17 EDT
OPEN
3.260
PREV CLOSE
3.230
HIGH
3.360
LOW
3.220
VOLUME
1.83M
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
2.400
MARKET CAP
725.16M
P/E (TTM)
-3.1814
1D
5D
1M
3M
1Y
5Y
10-Q: AGENUS INC
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward Looking Statements This...
Edgar Online - (EDG = 10Q, 10K) · 05/07 20:15
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN), Madrigal Pharmaceuticals (MDGL) and ObsEva
SmarterAnalyst · 05/07 15:55
Agenus shares fall after Q1 topline miss
Agenus (AGEN) shares fall 3% during premarket trading after the company posted first-quarter revenue that missed Wall Street estimates. The company's Q1 revenue fell 23% to $11.72M, missing analysts' average estimate by $2.81M.The
Seekingalpha · 05/06 13:06
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 12:55
Agenus Q1 EPS $(0.27) Beats $(0.31) Estimate, Sales $12.00M Miss $14.53M Estimate
Agenus (NASDAQ:AGEN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 35 percent decrease over losses of $(0.20) per share from the same
Benzinga · 05/06 12:09
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 11:49
BRIEF-Agenus Posts Q1 Loss Per Share $0.27
reuters.com · 05/06 11:48
Agenus EPS beats by $0.04, misses on revenue
Agenus (AGEN): GAAP EPS of -$0.27 beats by $0.04.Revenue of $11.72M (-22.5% Y/Y) misses by $2.81M.Shares +1.2% PM.Press Release
Seekingalpha · 05/06 11:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGEN. Analyze the recent business situations of Agenus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGEN stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 113.17M
% Owned: 50.88%
Shares Outstanding: 222.44M
TypeInstitutionsShares
Increased
33
5.76M
New
7
172.09K
Decreased
23
1.08M
Sold Out
9
472.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Garo Armen
President/Chief Operating Officer
Jennifer Buell
Chief Accounting Officer/Vice President - Finance
Christine Klaskin
Vice President
Donald Vidic
Vice President
Don Vidic
General Counsel
Adam Krauss
Other
Andy Hurley
Lead Director/Independent Director
Timothy Wright
Director
Paul Clark
Director
Susan Hirsch
Independent Director
Brian Corvese
Independent Director
Allison Jeynes-Ellis
Independent Director
Wadih Jordan
Independent Director
Ulf Wiinberg
No Data
  • All
  • Financials
  • Insiders
More
About AGEN
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.